Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

56.87 -0.35 (-0.61%)
Streaming Delayed Price Updated: 9:45 AM EDT, Oct 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
42 43 Next >
Bristol Myers Squibb Announces New Prescription Drug User Fee Act Goal Date for Reblozyl® (luspatercept-aamt) Supplemental Biologics License Application
From Bristol Myers Squibb
Via Business Wire
How Rivals Merck, Bristol Myers Benefit From Eli Lilly's FDA Snag
The Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher. 
Via Investor's Business Daily
Sunshine Biopharma's $8 Million Private Placement Injects New Funding For Drug Development
Image provided by the National Cancer Institute on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing... 
Via Benzinga
20 Dividend Growth Stocks: Safety, Income, Value And High Return
There are several sources of return that can be achieved by investing in common stocks. 
Via Talk Markets
Why is Nektar Therapeutics (NKTR) Stock Down Today?
Nektar Therapeutics is down big today after ending some of its clinical trials. What's going on with NKTR stock? 
Via InvestorPlace
The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
This Is What Whales Are Betting On Bristol-Myers Squibb
Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
Bristol Myers Sues AstraZeneca Over PD-L1 Cancer Drug Patents
Bristol Myers Squibb Co (NYSE: BMY) claims that AstraZeneca Plc's (NASDAQ: AZN) PD-L1 inhibitor, Imfinzi, infringed on at least eight patents in a newly filed complaint. 
Via Benzinga
Bristol Myers Squibb Embarks Oncology Pact With Volastra Therapeutics
Bristol Myers Squibb Co (NYSE: BMY) is pairing with New York-based biotech Volastra Therapeutics. 
Via Benzinga
FDA Approves Bristol-Myers' Opdualag, First LAG-3-Blocking Antibody Combo, For Melanoma Patients
The  
Via Benzinga
Bristol Myers Squibb to Demonstrate the Strength of its Growing Cardiovascular Portfolio at the American College of Cardiology’s 71st Annual Scientific Session
From Bristol Myers Squibb
Via Business Wire
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment... 
Via Benzinga
(BMY) - Analyzing Bristol-myers Squibb Company's Short Interest
Bristol-myers Squibb Company's (NYSE:BMY) short percent of float has risen 172.03% since its last report. The company recently reported that it has 70.88 million shares sold short... 
Via Benzinga
U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma
From Bristol Myers Squibb
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Markets Hold the Line after the Fed
Via Talk Markets
Why Eiger BioPharmaceuticals Stock Is Jumping Today
Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced data from the Phase 3 TOGETHER study evaluating Peginterferon Lambda in non-hospitalized COVID-19 adult patients at high risk of progressing to... 
Via Benzinga
Bristol-Myers Squibb And 2 Other Stocks Sold By Insiders
The Bank of England increased its key Bank Rate by 25bps to 0.75% during its recent meeting. Investors, meanwhile, focused on some notable insider trades When insiders sell shares... 
Via Benzinga
Top 3 Undervalued Dividend Growth Stocks in 2022
In turbulent times like what we are experiencing right now, blue-chip stocks that pay rising dividends can be a good choice. 
Via Talk Markets
7 Michael Burry Stocks to Buy as ‘The Big Short’ Investor Makes Moves
The famed investor has largely cashed out of equities, but you may want to check out these 7 Michael Burry stocks still in his portfolio. 
Via InvestorPlace
3 Top Stock Trades for This Week
Bulls seeking stock trades should focus on relative strength. Here are three stocks itching for new highs as the market sinks. 
Via InvestorPlace
Best Biotech Stocks To Buy In 2022
Biotechnology is the study of living creatures, biological systems, or derivatives to develop or improve healthcare products and therapies. This technology is connected with medical and... 
Via Talk Markets
Bristol Myers, Nektar Melanoma Doublet Therapy Trial Fails To Show Clinical Benefit
Bristol Myers Squibb Co (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) have an update following the first analysis of the Phase 3 PIVOT IO-001 study of... 
Via Benzinga
Nektar Therapeutics Loses Half Its Value As Bristol Myers-Paired Melanoma Test Flops
Sentiment was low heading into the study and analysts aren't hopeful for other tests. 
Via Investor's Business Daily
Why Nektar Therapeutics Shares Are Falling Today
Nektar Therapeutics (NASDAQ: NKTR) is trading significantly lower Monday morning after the company's Phase 3 PIVOT trial, in combination with Bristol-Myers Squibb Co (... 
Via Benzinga
Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma
From Bristol Myers Squibb
Via Business Wire
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
Bristol Myers, Eli Lilly And 2 Others Prove You Can Still Make Money In Medical Stocks
These four medical stocks are outperforming the lousy market for health care investors. 
Via Investor's Business Daily
Pfizer's Newest Way To Rival Bristol Myers Squibb Might Surprise You
Pfizer is one of the leading drug stocks today, and it's planning to rival another, Bristol. 
Via Investor's Business Daily
7 Drug Stocks to Consider After the Viatris Plunge
As Viatris and other generic drug makers plunge, what should you buy instead? Consider these seven well-known drug stocks, all of which are good value in what's still a pricey market. 
Via InvestorPlace
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.